Qiagen presents a stable but low-growth investment case, anchored by its consistent 63%+ gross margins and strong cash conversion, where FCF margin has held near 29.5% despite revenue growth decelerating to just 0.3% in 2026Q2.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has normalized to near-zero at 0.3% in 2026Q2 from a high of 7.5%, while gross margins have recovered fully to a stable 63.6% following the 2024Q2 anomaly, and SG&A discipline has helped expand operating margin to 24.7%.
QIAsymphony Connect represents a new generation of automated IVD nucleic acid extraction, combining proven performance with advanced capabilities.
Qiagen revised growth guidance for its QuantiFERON tuberculosis testing product, indicating potential expansion in this high-demand diagnostic segment.
The company is expanding its use of AI across research support and drug discovery workflows, potentially enhancing efficiency and innovation.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.65+3.7% vs $0.63 | $548M+1.7% vs $539M |
Q3 2026 Aug 5, 2026 | $0.62+3.7% vs $0.60 | $535M+1.4% vs $528M |
Q2 2026 May 6, 2026 | $0.54-0.4% vs $0.54 | $492M-0.8% vs $496M |
Q1 2026 Feb 4, 2026 | $0.62+1.6% vs $0.61 | $540M+2.3% vs $528M |
Qiagen N.V. ( QGEN ) Shareholder/Analyst Call November 6, 2026 8:00 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Presentation Roland Sackers CFO, MD & Member of Management Board Good morning, good afternoon.
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of Shareholders. Jon Pratt joined QIAGEN as Chief Executive Officer on September 1, 2026. Following today's shareholder approval, he joins Roland Sackers, Chief Financial Officer, on QIAGEN's Managing Board. Shar.
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.64 per share a year ago.
Benchmark QGEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Qiagen N.V. (QGEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $50.33 | $10.38B | 25.55 | 5.65% | 19.49% | 11.6% | 0.52% | |
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — | |
| $11.76 | $2.56B | -45.71 | -2.71% | -6.35% | -2.68% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $694.76 | $258.19B | 36.39 | 3.91% | 14.96% | 13.3% | 0.24% | |
| $230.25 | $161.86B | 37.58 | 2.9% | 16.91% | 8.18% | 0.54% |
Qiagen N.V. (QGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when QGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Qiagen N.V. (QGEN) stock FAQ — growth, dividends, profitability & financials explained
Qiagen N.V. (QGEN) reported $2.09B in revenue in fiscal year 2025, which is also its trailing twelve months. That is 3756% more than the $54.2M of fiscal year 1996.
Qiagen N.V. (QGEN) grew revenue by 3.0% over the trailing twelve months, compared with the twelve months before.
Yes. Qiagen N.V. (QGEN) earned $409.3M in net income over the trailing twelve months (a 19.5% net margin).
Yes. Qiagen N.V. (QGEN) pays a dividend that yields 0.52% at the current price, a small yield.
Qiagen N.V. (QGEN) had a return on equity (ROE) of 11.6% over the trailing twelve months. That is in line with the market's typical 10-15%.
Qiagen N.V. (QGEN) generated $447.7M in free cash flow over the trailing twelve months.
